News
Stay Up-To-Date on NEXT Oncology
- All
- NEXT Oncology Blog
- NEXT Oncology News
- Press Releases
Primary Results from the Randomized PHASE II RIGHT Choice Trial of Premenopausal Patients with Aggressive HR+/HER 2 Neu- Advanced Brest Cancer Treated with Ribociclib Endocrine Therapy versus Treatment of Physicians Choice Combination Chemotherapy.
Presented at SABCS 2022 by Len-Shu Lu from the National Taiwan University Hospital, Taipei Taiwan. Research remains an essential part of cancer care. In this blog, we will provide information ...
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that discovers novel target-antibody pairs through its unbiased interrogation of the human immune response, today announced the formation of an ...
Syneos Health Partners with Equicare, Optimizing Data Capture and Integration to Accelerate Clinical Trial Research
MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Equicare to use proXimity™, an innovative cloud-based ...
Evaluation of the Breast Cancer Index in Premenopausal women with Early Stage HR+ Breast Cancer in the Soft Trial.
Presented by Ruth O’ Regan et al. Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it ...
Grand Opening of joint venture brings access to proprietary Phase I program to more patients
NEXT-Virginia Opens Phase I Clinical Research Clinic for Oncology Patients in collaboration with Virginia Cancer Specialists. (SAN ANTONIO) January 9, 2023 –– Dr. Alexander I. Spira of Virginia Cancer Specialists (VCS) ...
ONXEO provides update on the Development Program for its first-in-class drug candidate AsiDNATM
Paris (France), January 25th, 2023 – 6pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative tumor ...
ADCs in Breast Oncology: Present & Future
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. ...
Pregnancy Outcome & Safety of Interrupting Therapy for Women with Endocrine ResponsIVE Breast Cancer.
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. ...
A New Paradigm in Breast Cancer Treatment: Treating HER 2 NEU Low-Expressing Breast cancer
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. ...
Pregnancy and Breast Cancer
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. ...